Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.
Website: | www.galectintherapeutics.com |
Main Phone: | +1 678 620-3186 |
Address: | 4960 Peachtree Industrial Boulevard |
Address 2: | Suite 240 |
State: | GA |
City / Town: | Norcross |
Country: | USA |
Postal Code: | 30071 |
Exchange: | NSC |
Employees: | 7 |
NAICS: | Pharmaceutical P |
Last Price 3.56 | Change $ 0.15 | Change % 4.40 | Tick N/A |
Bid 3.00 | Bid Size 200.00 | Ask 3.62 | Ask Size 500.00 |
Open 3.42 | High 3.62 | Low 3.38 | Prev Close 3.41 |
Last Trade | Volume 355,290 | 52 Wk Hi 6.74 | 52 Wk Low 1.28 |
Market Cap 133.7 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
Shares 37,569,866.00 | EPS (TTM) -0.49 | PE Ratio N/A | Exchange NCM |
|
|
Last 3 Mo | Last 12 Mo | |
---|---|---|
Number of Insider Trades | 0 | 4 |
Number of Buys | 0 | 1 |
Number of Sells | 0 | 3 |
Net Activity | 0 | -42746 |
Last 10 Buys | Shares |
---|---|
Arthur R. Greenberg | 1,000 |
Peter G. Traber | 1,000 |
Kevin D. Freeman | 1,000 |
Peter G. Traber | 1,000 |
Arthur R. Greenberg | 1,000 |
Kevin D. Freeman | 1,000 |
Peter G. Traber | 1,000 |
Peter G. Traber | 1,000 |
Peter G. Traber | 1,000 |
Peter G. Traber | 1,000 |
Last 10 Sell | Shares |
---|---|
James C. Czirr | 1,000 |
James C. Czirr | 1,000 |
Gilbert F. Amelio | 1,000 |
Gilbert F. Amelio | 1,000 |
Steven Prelack | 1,000 |
James C. Czirr | 1,000 |
Rod D. Martin | 1,000 |
James C. Czirr | 1,000 |
Rod D. Martin | 1,000 |
James C. Czirr | 1,000 |
Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
---|---|---|---|---|
High Target Price Estimate | 12 | 12 | 12 | 12 |
Low Target Price Estimate | 3 | 3 | 3 | 3 |
Mean Target Price Estimate | 7.67 | 7.67 | 7.67 | 7.67 |
Standard Deviation | 4.51 | 4.51 | 4.51 | 4.51 |
Date of Most Recent Estimate | 08/11/16 | 08/03/16 | 07/02/16 | 08/15/16 |
Form Type | Form Description | Pages | Date |
---|---|---|---|
S-3 | Simplified registration form | 29 | 2016-08-15 |
8-K | Report of unscheduled material events or corporate changes. | 9 | 2016-08-09 |
10-Q | Quarterly report with a continuing view of a company's financial position | 25 | 2016-08-09 |
8-K | Report of unscheduled material events or corporate changes. | 5 | 2016-08-02 |
8-K | Report of unscheduled material events or corporate changes. | 7 | 2016-06-20 |
CT ORDER | 1 | 2016-05-27 | |
8-K | Report of unscheduled material events or corporate changes. | 7 | 2016-05-16 |
8-K | Report of unscheduled material events or corporate changes. | 6 | 2016-05-11 |
8-K | Report of unscheduled material events or corporate changes. | 7 | 2016-05-10 |
10-Q | Quarterly report with a continuing view of a company's financial position | 45 | 2016-05-10 |
Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|
Strong Buy | 3 | 3 | 2 | 2 |
Moderate Buy | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 |
Moderate Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
Mean Rec. | 1 | 1 | 1 | 1 |